The "US POC/Point-of-Care Diagnostics Market Shares and Segment Forecasts 2017-2021: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers" report has been added to ResearchAndMarkets.com's offering.
The growing economic pressures on hospitals, coupled with advances in diagnostic technologies, intensifying competition among suppliers and physicians, and changing consumer demands are shifting diagnostic testing from hospitals and commercial laboratories closer to the patient.
This report provides a comprehensive analysis of the 10 major POC market segments, including their dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers.
This report covers the following:
- Five-year test volume and reagent sales forecasts for over 300 chemistry, immunodiagnostic, microbiology, hematology and coagulation procedures by market segment:
- Home/Personal Testing
- Routine and Special Chemistry
- Sales and market shares of major reagent and instrument suppliers.
- Analysis of over 130 diagnostic procedures.
- Review of leading chemistry, immunoassay, hematology and coagulation analyzers, both currently marketed and those in development, including their operating characteristics, features and selling prices.
- Emerging technologies and their applications for POC testing.
- Comprehensive listings of companies developing or marketing POC diagnostic technologies and products, by test.
- Assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, joint ventures, and new products in R&D.
- Specific opportunities for new POC instruments and reagent systems with potentially significant market appeal during the next five years.
- Design criteria for POC testing products.
- Alternative business expansion strategies.
- Potential market entry barriers and risks.
Companies Profiled
- Abbott
- ADI/American Diagnostica
- Alere/Biosite/Inverness
- Axis-Shield
- Beckman Coulter/Danaher
- Becton Dickinson
- Bio/Data
- Biomerieux
- Bio-Rad
- Cepheid
- Corgenix
- Diadexus
- Diagnocure
- Diagnostica Stago/Trinity Biotech
- Diamedix
- Eiken Chemical
- Fujirebio
- Grifols
- Helena Laboratories
- Hologic/Gen-Probe
- International Technidyne/Nexus DX
- Kreatech/Leica
- Kyowa Medex
- Ortho-Clinical Diagnostics
- Polymedco
- Qiagen
- Roche
- Sequenom
- Siemens
- Sysmex
- Takara Bio
- ThermoFisher
- Wako
- Zycare/Alere
For more information about this report visit https://www.researchandmarkets.com/research/ng5df6/us?w=4
View source version on businesswire.com: http://www.businesswire.com/news/home/20180119005726/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
